- Home
- NMRA vs BBNX Comparison
NMRA vs BBNX Comparison
Compare NMRA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | BBNX |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.0M | 493.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMRA | BBNX |
|---|---|---|
| Price | $2.00 | $9.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $6.57 | ★ $26.22 |
| AVG Volume (30 Days) | ★ 1.0M | 1.0M |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.99 |
| Revenue Next Year | N/A | $34.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $8.89 |
| 52 Week High | $3.65 | $32.71 |
Technical Indicators
Market Signals| Indicator | NMRA | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 31.86 |
| Support Level | $1.78 | N/A |
| Resistance Level | $2.20 | $11.92 |
| Average True Range (ATR) | 0.17 | 0.68 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 13.41 | 21.18 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.